Specialty Pharma Journal

ViiV Submits Fostemsavir NDA to the FDA for Treatment of HIV in Adults with Few Treatment Options Available

LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority owned…
Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder

TARRYTOWN, N.Y., Dec. 5, 2019 /PRNewswire/ — Results from initial 6-patient cohort show pozeli…
Bayer Collaborates with Children’s Hospital of Philadelphia to Research Novel Small Molecule Therapies for Oral Treatment of Hemophilia

WHIPPANY, N.J., Dec. 5, 2019 /PRNewswire/ — Bayer announced today that it has entered into a t…
Sage Therapeutics’ Investigational SAGE-217 Fails to Meet its Primary Endpoint in Pivotal Phase 3 Trial

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical c…
Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home

NIJMEGEN, Netherlands, Dec. 5, 2019 /PRNewswire/ — Enzyre, which is developing breakthrough am…

The 2017 Hepatitis C Treatment Landscape

February 22, 2017 Blog

Last year, 2016, brought a whirlwind of changes and progress to the hepatitis C field, …
Read More »
Understanding the Hepatitis C Testing Process

February 15, 2017 Blog
Potential New Medication for Lymphoma

February 8, 2017 Blog

Merck and Eisai Receive Third Breakthrough Therapy Designation from FDA for Keytruda Plus Lenvima Combination Treatment

July 24, 2019 FDA News, Oncology

KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United …

Acadia’s Pimavanserin Fails to Meet the Primary Endpoint in its Phase 3 Trial in Patients with Schizophrenia

July 24, 2019 Specialty Pharmacy

SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced top-line results from its Phase 3 …

Baxter Announces FDA Approval of Myxredlin, the First and Only Ready-to-Use Insulin for IV Infusion

July 24, 2019 Endocrinology, FDA News

DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, …

FDA Grants Orphan Drug Designation to Apic Bio’s APB-102 for the Treatment of Genetic SOD1 ALS

July 24, 2019 FDA News, Rare Diseases

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apic Bio, Inc., an innovative gene therapy company developing novel treatment options for …

FDA Approves Updated Imfinzi Label to Include Overall Survival Data in Unresectable, Stage III Non-Small Cell Lung Cancer

July 24, 2019 FDA News, Oncology

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved …

Vertex Submits NDA to the FDA for Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor in Cystic Fibrosis

July 23, 2019 FDA News, Pulmonary Diseases, Rare Diseases

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the submission of a New Drug Application (NDA) …

Takeda’s Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in its Phase 3 Crohn’s Disease Trial

July 23, 2019 Autoimmune Disorders, Crohn's Disease

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the VISIBLE …

Roche Expands Global Access Program Beyond HIV to Include Diagnostic Tests for Tuberculosis, Hepatitis and HPV

July 23, 2019 Business News, Hepatitis C, HIV/AIDS, Infectious Diseases

Basel, 22 July 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Global …

FDA Approves Celgene’s Otezla for the Treatment of Oral Ulcers Associated with Behçet’s Disease

July 23, 2019 FDA News, Rare Diseases

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) …

New Research Identifies Gene that Hides Cancer Cells from Immunotherapy

July 19, 2019 Oncology, Precision Medicine

SEATTLE — July 18, 2019 — A team at Fred Hutchinson Cancer Research Center has …

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs from Novartis

July 19, 2019 Business News

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three …

Amgen And Allergan’s MVASI (bevacizumab-awwb) and KANJINTI (trastuzumab-anns) Now Available in the United States

July 19, 2019 Biosimilars, Business News

THOUSAND OAKS, Calif., July 18, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Allergan plc(NYSE:AGN) today announced that MVASI™ (bevacizumab-awwb), a biosimilar …

FDA Accepts Horizon Therapeutics’ NDA to Make its Nephropathic Cystinosis Procysbi Available as Oral Granules in Packets

July 19, 2019 FDA News, Rare Diseases, Renal Diseases

DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration …

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics

July 18, 2019 Business News, Pulmonary Diseases

INGELHEIM, Germany & SEONGNAM, Korea–(BUSINESS WIRE)–Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they …

Predictive Oncology Subsidiary Helomics and UPMC Collaborate to Establish a Data and Artificial Intelligence-Driven Approach to Treating Ovarian Cancer

July 18, 2019 Business News, Oncology, Technology & Devices

PITTSBURGH, July 18, 2019 (GLOBE NEWSWIRE) — Predictive Oncology (Nasdaq: POAI) subsidiary Helomics, an artificial …

Page 30 of 274« First...10 20 28 293031 32 »40 50 60...Last »

Recent Posts